These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
521 related articles for article (PubMed ID: 32185622)
1. Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor. Ando T; Sano H; Yokoo M; Kusaba K; Kidoguchi K; Yamaguchi K; Katsuya H; Yoshihara S; Kubota Y; Kojima K; Kimura S Int J Hematol; 2020 Aug; 112(2):249-253. PubMed ID: 32185622 [TBL] [Abstract][Full Text] [Related]
2. Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation. Kida M; Kuroda Y; Kido M; Chishaki R; Kuraoka K; Ito T Int J Hematol; 2020 Aug; 112(2):243-248. PubMed ID: 32170661 [TBL] [Abstract][Full Text] [Related]
3. Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation. Zhang Z; Hasegawa Y; Hashimoto D; Senjo H; Kikuchi R; Chen X; Yoneda K; Sekiguchi T; Kawase T; Tsuzuki H; Ishio T; Ara T; Ohigashi H; Nakagawa M; Teshima T Bone Marrow Transplant; 2022 May; 57(5):775-780. PubMed ID: 35228711 [TBL] [Abstract][Full Text] [Related]
4. Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study. Nasilowska-Adamska B; Czyz A; Markiewicz M; Rzepecki P; Piatkowska-Jakubas B; Paluszewska M; Dzierzak-Mietla M; Solarska I; Borg K; Prochorec-Sobieszek M; Szydlo R; Lewandowski K; Skotnicki A; Jedrzejczak WW; Kyrcz-Krzemien S; Komarnicki M; Warzocha K Eur J Haematol; 2016 Mar; 96(3):236-44. PubMed ID: 25912052 [TBL] [Abstract][Full Text] [Related]
5. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197 [TBL] [Abstract][Full Text] [Related]
6. Myelomonocytic differentiation of leukemic blasts accompanied by differentiation syndrome in a case of Kondo T; Onozawa M; Fujisawa S; Harada S; Ogasawara R; Izumiyama K; Saito M; Morioka M; Mori A; Teshima T Hematology; 2021 Dec; 26(1):256-260. PubMed ID: 33631087 [No Abstract] [Full Text] [Related]
7. [Efficacy and safety of gilteritinib-based combination therapy bridging allo-HSCT in relapsed or refractory acute myeloid leukemia patients with positive FLT3-ITD mutation]. Xu Y; Zhang J; Xue SL; Miao M; Wang Y; Chen SN; Qiu HY; Wu DP Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):357-363. PubMed ID: 38951063 [No Abstract] [Full Text] [Related]
8. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. Brunet S; Labopin M; Esteve J; Cornelissen J; Socié G; Iori AP; Verdonck LF; Volin L; Gratwohl A; Sierra J; Mohty M; Rocha V J Clin Oncol; 2012 Mar; 30(7):735-41. PubMed ID: 22291086 [TBL] [Abstract][Full Text] [Related]
10. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Oran B; Cortes J; Beitinjaneh A; Chen HC; de Lima M; Patel K; Ravandi F; Wang X; Brandt M; Andersson BS; Ciurea S; Santos FP; de Padua Silva L; Shpall EJ; Champlin RE; Kantarjian H; Borthakur G Biol Blood Marrow Transplant; 2016 Jul; 22(7):1218-1226. PubMed ID: 27058617 [TBL] [Abstract][Full Text] [Related]
11. The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia. Altman JK; Perl AE; Hill JE; Rosales M; Bahceci E; Levis MJ Cancer Med; 2021 Feb; 10(3):797-805. PubMed ID: 33340276 [TBL] [Abstract][Full Text] [Related]
12. Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation. Xuan L; Wang Y; Huang F; Jiang E; Deng L; Wu B; Fan Z; Liang X; Xu N; Ye J; Lin R; Yin C; Zhang Y; Sun J; Han M; Huang X; Liu Q Cancer; 2018 May; 124(9):1954-1963. PubMed ID: 29509276 [TBL] [Abstract][Full Text] [Related]
14. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of Levis MJ; Hamadani M; Logan B; Jones RJ; Singh AK; Litzow M; Wingard JR; Papadopoulos EB; Perl AE; Soiffer RJ; Ustun C; Ueda Oshima M; Uy GL; Waller EK; Vasu S; Solh M; Mishra A; Muffly L; Kim HJ; Mikesch JH; Najima Y; Onozawa M; Thomson K; Nagler A; Wei AH; Marcucci G; Geller NL; Hasabou N; Delgado D; Rosales M; Hill J; Gill SC; Nuthethi R; King D; Wittsack H; Mendizabal A; Devine SM; Horowitz MM; Chen YB; J Clin Oncol; 2024 May; 42(15):1766-1775. PubMed ID: 38471061 [TBL] [Abstract][Full Text] [Related]
15. Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML. Wu S; Liu F; Gai Y; Carter J; Edwards H; Hüttemann M; Wang G; Li C; Taub JW; Wang Y; Ge Y Leuk Res; 2024 Sep; 144():107547. PubMed ID: 38968731 [TBL] [Abstract][Full Text] [Related]
16. Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling. Chen M; Shen C; Chen Y; Chen Z; Zhou K; Chen Y; Li W; Zeng C; Qing Y; Wu D; Xu C; Tang T; Che Y; Qin X; Xu Z; Wang K; Leung K; Sau L; Deng X; Hu J; Wu Y; Chen J Cell Rep Med; 2024 Jul; 5(7):101645. PubMed ID: 39019012 [TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT study. Kawashima N; Ishikawa Y; Atsuta Y; Sawa M; Ozawa Y; Hayashi M; Kohno A; Tomita A; Maeda T; Sakaida E; Usuki K; Hagihara M; Kanamori H; Matsuoka H; Kobayashi M; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H; Cancer Sci; 2020 Jul; 111(7):2472-2481. PubMed ID: 32391628 [TBL] [Abstract][Full Text] [Related]
18. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Chen YB; Li S; Lane AA; Connolly C; Del Rio C; Valles B; Curtis M; Ballen K; Cutler C; Dey BR; El-Jawahri A; Fathi AT; Ho VT; Joyce A; McAfee S; Rudek M; Rajkhowa T; Verselis S; Antin JH; Spitzer TR; Levis M; Soiffer R Biol Blood Marrow Transplant; 2014 Dec; 20(12):2042-8. PubMed ID: 25239228 [TBL] [Abstract][Full Text] [Related]
19. Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature. Arrigo G; D'Ardìa S; Audisio E; Cerrano M; Freilone R; Giai V; Secreto C; Urbino I; Frairia C Acta Haematol; 2022; 145(5):566-570. PubMed ID: 35580565 [TBL] [Abstract][Full Text] [Related]
20. Allogeneic Stem Cell Transplantation in Patients With FLT3-ITD Mutated AML: Transplantation in CR1 Is the Decisive Factor for Good Outcome. Jindra P; Raida L; Karas M; Szotkowski T; Lysák D; Hrabětová M; Jungová A; Steinerová K; Faber E; Papajík T Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):462-469. PubMed ID: 31109905 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]